News

Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.

Merck (NYSE:MRK) announced a partnership with The Hashgraph Group to build digital product traceability tools aligned with new EU transparency and compliance rules. The company is also working with global health authorities to explore use of its existing antiviral pill and vaccine technologies against the emerging Bundibugyo strain Ebola outbreak. Both developments highlight changes in Merck’s approach to supply chain authentication and infectious disease response that had not been covered...

MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.

Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.

Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials, and they plan global regulatory filings based on these data. At the same time, Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant...

Merck & Co., Inc. (NYSE:MRK) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. Reuters reported on June 1 that Merck & Co., Inc. (NYSE:MRK) is holding discussions with global health authorities about making its COVID-19 antiviral pill, molnupiravir, available as a treatment option for Ebola. The move came amid a growing […]

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

Health care's seasonal strength and defensive appeal are in focus, with Eli Lilly's growth and Merck's pipeline progress highlighted as key drivers.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho healthcare strategist Jared Holz reframed the sector, arguing that years of underperformance have turned drug stocks from a defensive holding into something more interesting for growth-heavy portfolios. “I think you just have to look ... Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

In recent days, Moderna and Merck reported five-year Phase 2b data showing that their personalized mRNA melanoma vaccine intismeran autogene, combined with Keytruda, substantially reduced the risk of cancer recurrence, metastasis, and death compared with Keytruda alone. At the same time, Moderna secured up to US$50.00 million in funding from CEPI for its Bundibugyo ebolavirus mRNA vaccine candidate, underscoring how its platform is being applied to both oncology and emerging infectious...

A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, ... SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks

Merck stock snapshot after recent performance Merck (MRK) has drawn investor attention after a period of steady share price movement, with the stock closing at US$120.79 and recording positive returns over the past week, month and past 3 months. At the same time, Merck reports annual revenue of US$65.8b and net income of US$8.9b, with both metrics showing annual growth. These figures help frame how recent price action lines up with the company’s current scale and profitability. See our latest...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. Moderna, Inc. and Merck & Co., Inc. (NYSE:MRK) announced on June 1 detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene in combination with KEYTRUDA® in patients with high-risk melanoma following […]

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.

Erasca Inc. (NASDAQ:ERAS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Erasca Inc. (NASDAQ:ERAS) announced a supply agreement and a clinical trial partnership with Merck. The collaboration is aimed at facilitating the AURORAS-1 clinical proof-of-concept research. This research thoroughly assesses the exclusive pan-RAS molecular glue ERAS-0015 […]

The seasonal strength lines up with major medical and scientific conferences that cluster during this period.

Merck (NYSE:MRK) has agreed to a settlement worth more than $50m to resolve over 200 lawsuits related to its Gardasil HPV vaccine. The settlement concludes a significant block of litigation while Merck continues to state that Gardasil is safe and effective. This development comes as Merck's share price stands at $120.26 and the stock has returned 60.6% over the past year. For investors watching Merck, the Gardasil settlement is a material legal event that helps clear a long running source...

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.